All In Biotech

Drug Trial Radar · NCT06360874

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Food Effect of ND-003 Tablets in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

104

Planned (sponsor's estimate)

Start

May 9, 2024

Primary completion

Dec 2024

Study completion Feb 2025

Sponsor

Sponsor type
Industry
Collaborators
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults

Conditions

  • Healthy

Interventions

  • ND-003 40mgDrug

    Participants receive 40mg ND-003 tablets once.

  • ND-003 placebo 40mgDrug

    Participants receive placebo tablet matching to receive 40mg of ND-003.

  • ND-003 80mgDrug

    Participants receive 80mg ND-003 tablets once.

  • ND-003 placebo 80mgDrug

    Participants receive placebo tablet matching to receive 80mg of ND-003.

  • ND-003 160mgDrug

    Participants receive 160mg ND-003 tablets once.

  • ND-003 placebo 160mgDrug

    Participants receive placebo tablet matching to receive 160mg of ND-003.

  • ND-003 240mgDrug

    Participants receive 240mg ND-003 tablets once.

  • ND-003 placebo 240mgDrug

    Participants receive placebo tablet matching to receive 240mg of ND-003.

  • ND-003 300mgDrug

    Participants receive 300mg ND-003 tablets once.

  • ND-003 placebo 300mgDrug

    Participants receive placebo tablet matching to receive 300mg of ND-003.

  • MAD_ND003_Dose 1Drug

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • MAD_placebo_Dose 1Drug

    Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 1

  • MAD_ND003_Dose 2Drug

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • MAD_placebo_Dose 2Drug

    Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 2

  • MAD_ND003_Dose 3Drug

    Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

  • MAD_ placebo_Dose 3Drug

    Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 3

  • Food effect_Cohort 1Drug

    Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.

  • Food effect_Cohort 2Drug

    Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AE)Time frame: through study completion, an average of 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.